51S Stock Chart & Stats
€0.14
€0.00(0.00%)
At close: 4:00 PM EDT
€0.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.78M
Enterprise Value€60.71M
Total Cash (Recent Filing)€2.59M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding243,454,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€19.27M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers financial risk for a clinical-stage biotech that faces recurring R&D spend and capital needs. This structural conservatism preserves optionality to raise equity or partner on favorable terms, reduces interest burden, and provides flexibility during multi-year development cycles.
Scalable Allogeneic Cymerus PlatformAn off-the-shelf iPSC-derived MSC manufacturing platform is a durable competitive asset: it enables large-scale, standardized production across indications, supports licensing/partnering, and can lower per-dose cost. Scalability and multi-indication utility underpin long-term commercial and partnership opportunities.
Very High Gross Margins On Reported RevenueNear-100% gross margins on the firm's limited revenues indicate favorable product-level economics once scale is achieved. High gross margins imply operating leverage: after fixed R&D and SG&A are managed or offset via partnerships, incremental revenues could flow to the bottom line more directly.
Bears Say
Persistent Operating LossesSustained, large operating losses signal the company remains far from break-even and that R&D and overhead outstrip current revenue generation. Over multiple quarters this erodes investor capital, hampers reinvestment capacity, and prolongs dependence on external funding to advance clinical programs.
Negative Operating And Free Cash FlowChronic negative operating and free cash flow creates structural funding pressure: the company must repeatedly access equity or partner milestone payments, which risks dilution and can delay development timelines if financing terms tighten, constraining long-term program execution.
Declining Equity And Total AssetsMaterial declines in equity and assets reflect cumulative losses and shrinking balance-sheet capacity. This erosion reduces strategic flexibility, limits runway for independent development, and increases urgency to secure non-dilutive partnerships or financing, raising execution risk over the coming months.
Cynata Therapeutics Limited News
51S FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was €0.06 and its highest was €0.24 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is €1.78M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 27 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 26, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 243,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:51S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:51S Sentiment 69%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―